Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 4/4/2020
SIETES contiene 92956 citas

 
 
 1 a 20 de 73 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Law SWY, Wong AYS, Anand S, Wong ICK, Chan EW. Neurospychiatric events associated with leukotriene-modifying agents: a systematic review. Drug Saf 2018;41:marzo. [Ref.ID 102559]
3. Cita con resumen
Anónimo. Long-acting beta2 agonists for childhood asthma. Australian Prescriber 2012;35:111-3. [Ref.ID 93160]
4. Cita con resumen
5. Cita con resumen
Schumock GT, Lee TA, Joo MJ, Valuck RJ, Stayner LT, Gibbons RD. Association between leukotriene-modifying agents and suicide: what is the evidence?. Drug Saf 2011;34:533-44. [Ref.ID 90892]
6. Cita con resumen
Reuben A, Koch DG, Lee WM, Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:2065-76. [Ref.ID 89970]
8. Cita con resumen
Azaparren Andía A. Lugar de los leucotrienos en la terapéutica infantil. Boletín de Información Farmacoterapéutica de Navarra 2009;17:1-12. [Ref.ID 86006]
9. Cita con resumen
Fanta CH. Asthma. N Engl J Med 2009;360:1002-14. [Ref.ID 85400]
10.
Twaites BR, Wilton LV, Shakir SAW. Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England. Drug Saf 2007;30:419-29. [Ref.ID 80155]
11.
Anónimo. Antagonisti dei recettori per i leucotrieni. Informazioni sui Farmaci 2006;30:14-8. [Ref.ID 76718]
12.Tiene citas relacionadas Cita con resumen
Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, et al.. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005;352:1519-28. [Ref.ID 73403]
13.
Currie GP, Devereux GS, Lee DKC, Ayres JG. Recent developments in asthma management. BMJ 2005;330:585-9. [Ref.ID 73112]
14. Cita con resumen
Anónimo. Zafirlukast. Reports of serious hepatic events. Canada. WHO Pharmaceuticals Newsletter 2004;3:7. [Ref.ID 70840]
15. Cita con resumen
Sin DD, Man J, Sharpe H, Gan WQ, Man SFP. Pharmacological management to reduce exacerbations in adults with asthma. A systematic review and meta-analysis. JAMA 2004;292:367-76. [Ref.ID 70790]
16.
Snyder L, Blanc PD, Katz PP, Yelin EH, Eisner MD. Leukotriene modifier use and asthma severity. Arch Intern Med 2004;164:617-22. [Ref.ID 69620]
17.
García-Marcos L, Schuster A, Pérez-Yarza E G. Benefit-risk assessment of antileukotriens in the management of asthma. Drug Saf 2003;26:483-518. [Ref.ID 66445]
19. Cita con resumen
Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 2003;361:587-94. [Ref.ID 65165]
Seleccionar todas
 
 1 a 20 de 73 siguiente >>